Date: 2013-05-23
Type of information: R&D agreement
Compound: novel chelating agents
Company: Roche (Switzerland) Macrocyclics (an AREVA Med company) (USA)
Therapeutic area: Cancer - Oncology
Type agreement: R&D
Action mechanism:
Disease:
Details: * On May 23, 2013, Macrocyclics, an Areva Med company, has announced a new collaborative research agreement with Roche for the continued development of novel chelating agents designed specifically by Macrocyclics for Roche\'s applications. The new project will build on established expertise related to lead-212 (212Pb) and novel chelate architecture for radioimmunotherapy. Last year, Roche and Areva Med have already entered into astrategic collaboration to create a novel, advanced alpha radio-immunotherapy platform to target and kill cancer cells.
Financial terms:
Latest news:
